Subsidiary of Jiangsu Lianhuan Pharmaceutical (600513.SH), Lincomycin Hydrochloride Injection, passed the generic drug consistency evaluation.

Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that its holding subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd. (referred to as "Changle Pharmaceutical"), recently received the approval notice issued by the National Medical Products Administration for the supplementary application of Lincomycin Hydrochloride Injection, approving Changle Pharmaceutical's product to pass the generic drug quality and efficacy consistency evaluation. Lincomycin Hydrochloride Injection (specification: 2ml:0.6g) belongs to the lincosamide class of antibiotics and is clinically used for diseases such as respiratory tract infections, skin and soft tissue infections, and bone and joint infections caused by sensitive bacteria. Data from IMS Health Database shows that the sales revenue of Lincomycin Hydrochloride Injection (specification: 2ml:0.6g) in domestic sample hospitals in 2024 was 10.8176 million yuan.